Full metadata record
DC FieldValueLanguage
dc.contributor.authorVALLON M.en_GB
dc.contributor.authorSEIDL C.en_GB
dc.contributor.authorBLECHERT B.en_GB
dc.contributor.authorLI Zhouleien_GB
dc.contributor.authorGILBERTZ K.-P.en_GB
dc.contributor.authorBAUMGART Anjaen_GB
dc.contributor.authorAICHLER Men_GB
dc.contributor.authorFEUCHTINGER Aen_GB
dc.contributor.authorGAERTNER F. C.en_GB
dc.contributor.authorBRUCHERTSEIFER Franken_GB
dc.contributor.authorMORGENSTERN Alfreden_GB
dc.contributor.authorWALCH Axel K.en_GB
dc.contributor.authorSENEKOWITSCH-SCHMIDTKE R.en_GB
dc.contributor.authorESSLER M.en_GB
dc.date.accessioned2012-11-28T01:02:09Z-
dc.date.available2012-11-27en_GB
dc.date.available2012-11-28T01:02:09Z-
dc.date.created2012-11-26en_GB
dc.date.issued2012en_GB
dc.date.submitted2012-11-13en_GB
dc.identifier.citationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 39 p. 1886 - 1897en_GB
dc.identifier.issn1619-7070en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC76583-
dc.description.abstractTargeted therapy with α-particle emitting radionuclidesis a promising new option in cancer therapy. Stable conjugates of the vascular tumour-homing peptide F3 with the α-emitter 213Bi specifically target tumour cells. The aim of our study was to determine efficacy of combined 213Bidiethylenetriaminepentaacetic acid (DTPA)-F3 and paclitaxel treatment compared to treatment with either 213Bi-DTPAF3 or paclitaxel both in vitro and in vivo. Methods Cytotoxicity of treatment with 213Bi-DTPA-F3 and paclitaxel, alone or in combination, was assayed towards OVCAR-3 cells using the alamarBlue assay, the clonogenic assay and flow cytometric analyses of the mode of cell death and cell cycle arrest. Therapeutic efficacy of the different treatment options was assayed after repeated treatment of mice bearing intraperitoneal OVCAR-3 xenograft tumours. Therapy monitoring was performed by bioluminescence imaging and histopathologic analysis. Treatment of OVCAR-3 cells in vitro with combined 213Bi-DTPA-F3 and paclitaxel resulted in enhanced cytotoxicity, induction of apoptosis and G2/M phase arrest compared to treatment with either 213Bi-DTPA-F3 or paclitaxel. Accordingly, i.p. xenograft OVCAR-3 tumours showed the best response following repeated (six times) combined therapy with 213Bi-DTPA-F3 (1.85 MBq) and paclitaxel (120 μg) as demonstrated by bioluminescence imaging and histopathologic investigation of tumour spread on the mesentery of the small and large intestine. Moreover, mean survival of xenograft mice that received combined therapy with 213Bi-DTPA-F3 and paclitaxel was significantly superior to mice treated with either 213Bi-DTPA-F3 or paclitaxel alone. Combined treatment with 213Bi-DTPA-F3 and paclitaxel significantly increased mean survival of mice with peritoneal carcinomatosis of ovarian origin, thus favouring future therapeutic application.en_GB
dc.description.sponsorshipJRC.E.5-Nuclear chemistryen_GB
dc.format.mediumPrinteden_GB
dc.languageENGen_GB
dc.publisherSPRINGERen_GB
dc.relation.ispartofseriesJRC76583en_GB
dc.titleEnhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arresten_GB
dc.typeArticles in periodicals and booksen_GB
dc.identifier.doi10.1007/s00259-012-2203-zen_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.